Unshackling the TP53 in leukaemia with a novel combination approach.
Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. However, they might be useful if they were combined.
Researchers at the Sanford Burnham Prebys Medical Discovery Institute and the University of Glasgow have early proof a combination strategy may work in AML.
Combining MDM2 and BET inhibitors enhanced the eradication of AML cell lines in lab studies and were more effective than solo treatment in killing cancer in mouse models. The researchers stated in the journal Na...
